DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: lopinavir; ritonavir

Summary for Generic Name: lopinavir; ritonavir

Tradenames:1
Patents:25
Applicants:1
NDAs:3
Drug Master File Entries: see list10
Suppliers: see list7
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Tentative approvals for LOPINAVIR; RITONAVIR

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL200MG; 50MG
<disabled><disabled>TABLET; ORAL200MG; 50MG
<disabled><disabled>TABLET; ORAL100MG; 25MG

Clinical Trials for: lopinavir; ritonavir

TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.
Status: Completed Condition: HIV

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole
Status: Completed Condition: Pharmacokinetics of Isavuconazole; Pharmacokinetics of Lopinavir/Ritonavir; Healthy Volunteers

Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
Status: Completed Condition: Acquired Immunodeficiency Syndrome

Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin
Status: Not yet recruiting Condition: AIDS; Tuberculosis

Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
Status: Completed Condition: HIV-1 Infections

Safety and Effectiveness of World Health Organization Dosing Guidelines of Lopinavir/Ritonavir for Children
Status: Completed Condition: HIV

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906Oct 28, 2005RXYes8,691,878*PED<disabled>Y
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906Oct 28, 2005RXYes8,470,347*PED<disabled>Y
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906Oct 28, 2005RXYes8,399,015*PED<disabled>Y
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906Oct 28, 2005RXYes8,377,952*PED<disabled>Y
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc